HEPATOCELLULAR CARCINOMA

This study tests a treatment called multimodal thermal therapy (MTT) that uses both freezing and heating to destroy liver tumors. The goal is to see if this approach can control the cancer and also activate the body's immune system to fight it. About 120 adults with liver cancer …

This early-stage trial tests a new drug called FXB0871 in adults with advanced solid tumors, including lung and liver cancers, that have not responded to standard treatments. The study aims to find the safest dose and check if the drug can shrink tumors. About 138 participants wi…

This study tests a new first-line treatment for people with advanced liver cancer that cannot be removed by surgery. The treatment combines a procedure that delivers chemotherapy directly to the tumor (TACE) with two drugs that boost the immune system and block blood vessel growt…

This early-phase study looks at whether adding peginterferon alfa-2β to standard antiviral drugs can improve outcomes for people with hepatitis B-related liver cancer after their tumor is surgically removed. About 156 adults aged 18 to 65 will receive either the combination or an…

This study looks at whether combining local treatments (like radiation or chemo directly to the tumor) with targeted drugs and immunotherapy can shrink liver cancer enough for patients who don't currently qualify for a transplant. About 300 patients will be followed to see how ma…

This study tests a new way to treat liver cancer that cannot be removed by surgery. Doctors will use tiny drug-coated beads to block blood flow to the tumor and combine this with a targeted drug called Donafenib. The goal is to see if this approach can shrink tumors and help peop…

This early-stage trial tests a new drug called TB511, alone or with pembrolizumab, in 12 adults with advanced solid tumors (lung, prostate, colorectal, or liver cancer) that stopped responding to standard treatments. The goal is to find the safest dose and see if it can shrink tu…

This study tests whether adding the experimental drug zanzalintinib to the approved drug durvalumab can help people with advanced liver cancer live longer. It is for patients whose cancer was stable or improved after initial treatment with tremelimumab and durvalumab. About 16 ad…

This study tests a combination of three drugs (gecacitinib, donafenib, and a PD-1 inhibitor) as a second treatment for people with advanced liver cancer that got worse after initial immunotherapy. The goal is to see if this new mix can shrink tumors or slow the cancer safely. Abo…

This study tests a new treatment for people with advanced liver cancer that cannot be surgically removed. The treatment combines low doses of two drugs (bevacizumab and atezolizumab) with a procedure that delivers chemotherapy directly to the liver. The goal is to see if this app…

This study tests whether giving a combination of drugs (sintilimab, bevacizumab, and chemotherapy) before surgery can lower the chance of liver cancer returning in patients at high risk. About 100 adults with resectable liver cancer and high-risk features will be randomly assigne…

This study compares two treatments for people with liver cancer that cannot be removed by surgery. One group gets a standard procedure (TACE) plus a three-drug pill regimen, while the other gets TACE plus standard targeted therapy and immunotherapy. The goal is to see which combi…

This pilot study tests whether adding immune-boosting drugs (cemiplimab with or without fianlimab) after a standard radiation treatment (Y90) can help control liver cancer. About 20 adults with liver cancer will be enrolled. The goal is to see if the combination slows cancer grow…

This study looks back at medical records of 300 people with liver cancer that could not be removed by surgery. About 100 received a mix of local treatments (like TACE or radiation) plus targeted therapy and immunotherapy to try to shrink their tumors. The goal is to see how many …

This study tests whether adding an experimental drug called GKL-006 to a standard procedure (TACE) can shrink liver tumors that cannot be surgically removed. About 48 adults with advanced liver cancer will receive either the combination or TACE alone. The main goal is to see how …

This study tests a new drug called MRG006A combined with standard immunotherapy and targeted therapy for people with advanced liver cancer that cannot be removed by surgery. The goal is to find a safe dose and see if the combination helps control the cancer. About 160 adults with…

This early-stage study tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells that carry a protein called…

This study tests a precise radiation treatment (Yttrium-90) for people with liver cancer that cannot be surgically removed. The treatment delivers tiny radioactive beads directly to the tumor's blood supply to shrink it. The goal is to see how well it controls the cancer and whet…

This study tests whether adding radiotherapy to a standard immunotherapy-plus-bevacizumab regimen can shrink liver tumors enough to allow surgery. Sixty adults with unresectable, non-spreading liver cancer will be randomly assigned to receive either the triple combination or the …

This is the first human study of an experimental oral drug called ACC-1898 for adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and understand how the body processes the drug. Participants will take dail…

This study tests a new way to use contrast-enhanced ultrasound (CEUS) to see if liver cancer treatment (ablation) worked completely. Researchers will compare CEUS results with standard CT or MRI scans in 200 adults. If accurate, this method could reduce the need for radiation or …

This study looks at whether adding nanocrystalline megestrol acetate to standard treatment can improve appetite and body mass index (BMI) in people with advanced liver cancer who are experiencing cachexia (severe weight loss and muscle wasting). About 68 participants will be rand…

This study tests an artificial intelligence (AI) model that analyzes medical images and other data to predict how well liver cancer patients will respond to a combination of treatments: TACE (a procedure that blocks blood flow to the tumor), immunotherapy, and targeted therapy. T…

This study will follow 1,000 adults who have liver or bile duct surgery at San Jacopo Hospital in Pistoia. Researchers will track complications, survival, and cancer recurrence for up to 5 years. The goal is to better understand how patients recover and their long-term outcomes a…

This study looks back at medical records of 200 liver cancer patients in Austria to see if getting an mRNA COVID-19 vaccine within three months before starting immunotherapy improves their response to cancer treatment. Researchers will also check if vaccination affects survival o…

This study tests a special MRI machine that looks at phosphorus and sodium levels in the liver. Researchers will compare images from 100 people—some with liver cancer and some healthy—to see if these scans can help tell the difference. The goal is to improve how doctors detect an…